News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
SCS Capital Management LLC acquired 612,850 shares of Agios Pharmaceuticals (NASDAQ:AGIO) during the second quarter, valued at approximately $22.7 million. The biopharmaceutical company reported a quarterly loss per share of $1.69, missing estimates, but exceeded revenue expectations with $44.75 million. Analyst sentiment for AGIO …
This article provides an in-depth AI-driven analysis for Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It details institutional trading strategies with specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging. …
Emergent Biosolutions Inc. (NYSE:EBS) has received an average "Hold" rating from analysts, with an average 12-month price target of $10.00. The company recently reported better-than-expected quarterly EPS of $0.60 and revenue of $234.3 million, though it posted a negative net margin and analysts anticipate …
Pulse Biosciences (PLSE) recently announced a $75 million at-the-market equity offering and reported wider second-quarter losses, impacting existing shareholders. Despite strong recent share price performance, with a 30-day return of 55.30% and a year-to-date return of 232.64%, the stock now trades above the latest …
Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, …
This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.
Walleye Capital LLC has acquired a new stake of 347,898 shares in Tyra Biosciences, Inc. (NASDAQ:TYRA), valued at approximately $11.1 million, bringing institutional ownership in the company to 84.14%. Despite the stock opening at $25.29, well below its 52-week high, analysts maintain a "Moderate …
Walleye Capital LLC has acquired 386,183 shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the second quarter, a new stake valued at approximately $14.4 million. This purchase represents 0.44% of IDEAYA Biosciences. Despite a reported quarterly loss of $1.22 per share, institutional ownership of the …
Forte Biosciences, Inc. (NASDAQ:FBRX) has received an average "Hold" rating from seven brokerages, with an average 12-month price target of $72.50, below its current $76.83 stock price. Recent analyst coverage has generally been negative, including downgrades from Wall Street Zen, Weiss Ratings, Barclays, and …
Assembly Biosciences (NASDAQ:ASMB) has received an average "Moderate Buy" recommendation from brokerages, with five out of seven analysts rating the stock a buy. The average 12-month price target for ASMB is $44.00, significantly higher than its recent price of $32.95. The company also reported …
The California State Teachers Retirement System significantly increased its stake in MBX Biosciences by 1,197.9%, now holding 22,765 shares valued at $680,000. Other institutional investors also raised their positions in the company. Despite the company missing its Q2 earnings estimates, analysts maintain a "Moderate …
Dimensional Fund Advisors LP has acquired a new stake worth $1.40 million in MBX Biosciences, Inc., representing 0.10% of the company. Other institutional investors have also increased their positions in MBX. Despite missing earnings estimates for the recent quarter, analysts generally maintain a "Moderate …
IDEAYA Biosciences (NASDAQ:IDYA) has received an average rating of "Moderate Buy" from sixteen brokerages, with an average 12-month price target of $50.13, significantly above its current share price of $36.30. The company's recent quarterly results showed revenue exceeding expectations but missed on earnings per …
T. Rowe Price Associates has reported a beneficial ownership of 3,634,470 shares of Twist Bioscience Corp. (TWST), representing a 5.8% stake in the company's common stock. The firm holds sole voting power over 3,520,536 shares and sole dispositive power over all 3,634,470 shares, as …
Wall Street Zen downgraded IDEAYA Biosciences (NASDAQ:IDYA) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $50.12. The company's shares opened at $36.30, and it recently reported a quarterly loss of $1.22 per share, …
Angel Studios CEO Neal Harmon recently purchased over $125,000 worth of company stock, acquiring 29,035.659 shares at an average price of $4.3053. This purchase comes as the stock has seen a 34% gain over the last six months despite a 66% decline over the …
Skye Bioscience announced its definitive agreement to acquire Redx Pharma through a scheme of arrangement under U.K. law for an approximate $125 million deal. The merged entity will be known as Fibrx Therapeutics Inc., trading on Nasdaq, and will be led by Redx's current …
TuHURA Biosciences anticipates preliminary results from its IFX-2.0 study, which combines IFX-2.0 with Keytruda for treating deep-seated Merkel Cell Carcinoma (MCC). These results are expected in the first half of 2027. This study represents a key milestone for TuHURA Biosciences in its development of …
Bright Minds Biosciences (NASDAQ:DRUG) reported quarterly earnings per share of ($0.17), significantly surpassing analysts' consensus estimate of ($1.28). Following the announcement, shares fell 2.0% to $76.44. Analysts maintain a generally positive outlook on the stock, with an average "Buy" rating and a consensus price …
Castle Biosciences Inc (CSTL) shares recently dropped 3.0%, leading to a 7.5% decrease over the past week, but GuruFocus' GF Value indicates the stock is slightly undervalued. Despite a strong GF Score of 81/100, driven by high growth potential, the company faces significant challenges …
Perceptive Advisors LLC and related entities, including Joseph Edelman, have reported a beneficial ownership of 12,046,579 shares in Solid Biosciences Inc. (NASDAQ: SLDB), representing an 11.2% stake. This includes common stock and pre-funded warrants, with the latter subject to a 9.99% beneficial ownership limitation …
A holder of CSTL common stock has filed a notice of intent to sell up to 24,908 shares on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The indicated aggregate market value of these shares is $741,493.72, and they originated from restricted …
Twist Bioscience Corp (TWST) shares dropped by 5.4% to $118.57, yet the stock is considered 126.4% overvalued compared to its GF Value™ of $52.38. Despite a strong growth rank of 10/10, the company's profitability and valuation ranks are low, coupled with significant insider selling …
Search by ticker symbol or company name and select a result to open its chart.